Mineralys Therapeutics (MLYS) Net Income towards Common Stockholders (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Net Income towards Common Stockholders data on file, last reported at -$45.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 2.01% year-over-year to -$45.3 million; the trailing twelve-month figure through Mar 2026 stood at -$317.8 million (down 12.93% YoY), and the FY2025 full-year result was -$316.9 million, down 16.37% from the prior year.
• Net Income towards Common Stockholders rose to -$45.3 million in Q1 2026, from -$184.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$6.5 million in Q2 2022 to a low of -$184.6 million in Q4 2025.
• A 5-year average of -$45.1 million and a median of -$35.4 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders tumbled 360.99% in 2024 and surged 31.57% in 2025, its largest moves.
• Tracing MLYS's Net Income towards Common Stockholders over 5 years: stood at -$25.6 million in 2022, then declined by 11.73% to -$28.6 million in 2023, then plunged by 360.99% to -$131.7 million in 2024, then plunged by 40.17% to -$184.6 million in 2025, then surged by 75.44% to -$45.3 million in 2026.
• Business Quant data shows MLYS's Net Income towards Common Stockholders at -$45.3 million in Q1 2026, -$184.6 million in Q4 2025, and -$41.1 million in Q3 2025.